RxDoctor Payments Data

Ossama Maher

Pediatric Hematology-Oncology · Miami, FLNPI 1245663087

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Day One Biopharmaceuticals at 51.8% of the total. 2025 is the largest year on record at $4,282, more than ten times the $336 reported in 2019.

$5,989in general payments, 2019–2025

Across 88 payments — averaging $68.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Day One Biopharmaceuticals$3K
  • Novartis$898
  • Sobi, Inc$519
  • AstraZeneca$288
  • Sanofi-aventis U.S. LLC$150
  • Incyte Corporation$147
  • plus $886 from 20 others
$54,572in research payments, 2019–2025

Across 8 payments — averaging $6821.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Day One Biopharmaceuticals$23K
  • Bayer$21K
  • Chiesi USA, Inc.$10K

What the payments were for

  • Consulting fees$1753%
  • Speaking & faculty fees$2,99850%
  • Food & beverage$2,76946%
  • Education$481%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,989 in reported general payments places this provider in the 80th percentile of 132 pediatric hematology-oncology providers in Florida.

See all pediatric hematology-oncology providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezurockBelumosudil Mesylate12$205,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCRezurock$150$205,00612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 132 pediatric hematology-oncology providers in Florida.

Other pediatric hematology-oncology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →